AVTR: Avantor, Inc. Stock

by  •  • Comments Off on AVTR: Avantor, Inc. Stock

SIC 3826 – Laboratory Analytical Instruments

Valuation
Market Cap ($M) 11,017.00
Enterprise Value ($M) 14,810.90
Book Value ($M) 5,956.70
Book Value / Share 8.75
Price / Book 1.85
NCAV ($M) -4,011.20
NCAV / Share -5.89
Price / NCAV -2.75

Profitability (mra)
Return on Invested Capital (ROIC) 0.07
Return on Assets (ROA) 0.06
Return on Equity (ROE) 0.13

Liquidity (mrq)
Quick Ratio 0.70
Current Ratio 1.07

Balance Sheet (mrq) ($M)
Current Assets 2,146.60
Assets 12,114.50
Liabilities 6,157.80
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 6,783.60
Operating Income 638.20
Net Income 711.50
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 840.80
Cash from Investing 438.90
Cash from Financing -1,281.20

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-14 13G/A T. Rowe Price Investment Management, Inc. 6.10 -38.37
02-13 13G/A Dodge & Cox 14.60 44.41
08-07 13G/A BlackRock, Inc. 10.80 59.97

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-02-07 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTI
2024-10-25 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT
2024-07-26 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO S
2024-04-26 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-03-31 1,226,088 4,425,762 27.70
2025-03-28 1,568,982 4,259,083 36.84
2025-03-27 1,160,263 3,274,408 35.43
2025-03-25 2,402,106 5,991,090 40.09

(click for more detail)

Similar Companies
A – Agilent Technologies, Inc. AME – AMETEK, Inc.
BIO – Bio-Rad Laboratories, Inc. BIO.B – Bio-Rad Laboratories, Inc.


Financial data and stock pages provided by
Fintel.io